Circulating Biomarkers for Duchenne Muscular Dystrophy

Area of Science:

• Biochemistry
• Genetics
• Molecular Biology

Background:

• Duchenne muscular dystrophy (DMD) is a common genetic disorder.
• Research has identified disease mechanisms and potential therapeutic targets.
• High-throughput omics technologies offer insights into dystrophic muscle changes.

Purpose of the Study:

• To review circulating biomarkers for tracking DMD progression.
• To assess biomarkers for monitoring therapeutic response in DMD patients.
• To highlight the role of biomarkers as surrogate endpoints in drug development.

Main Methods:

• Literature review of transcriptomic, proteomic, metabolomic, and lipidomic biomarkers.
• Analysis of data from murine and canine animal models.
• Evaluation of biomarkers identified in muscle tissue, serum, and urine.

Main Results:

• Various circulating biomarkers have been identified through omics studies.
• Animal models have been crucial in profiling candidate biomarkers.
• Biomarkers can reflect changes in dystrophic muscles and body fluids.

Conclusions:

• Circulating biomarkers can effectively track Duchenne muscular dystrophy progression.
• Biomarkers are valuable for evaluating patient response to novel therapies.
• Biomarkers can facilitate regulatory approval processes for new DMD treatments.